{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T13:10:12Z","timestamp":1708175412829},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1007\/s11904-007-0018-5","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T16:32:20Z","timestamp":1187368340000},"page":"119-125","source":"Crossref","is-referenced-by-count":2,"title":["Considering metabolic issues when initiating HIV therapy"],"prefix":"10.1007","volume":"4","author":[{"given":"David Alain","family":"Wohl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,18]]},"reference":[{"key":"18_CR1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","volume":"40","author":"P. Bacchetti","year":"2005","unstructured":"Bacchetti P, Gripshover B, Grunfeld C, et al.: Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121\u2013131.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"18_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00126334-200211010-00001","volume":"31","author":"M. Schambelan","year":"2002","unstructured":"Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257\u2013275.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"18_CR3","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","volume":"14","author":"A. Carr","year":"2000","unstructured":"Carr A, Miller J, Law M, et al.: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution of protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25\u201332.","journal-title":"AIDS"},{"key":"18_CR4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1086\/507333","volume":"43","author":"D.A. Wohl","year":"2006","unstructured":"Wohl DA, McComsey G, Tebas P, et al.: Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006, 43:645\u2013653.","journal-title":"Clin Infect Dis"},{"key":"18_CR5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/01.qai.0000138420.38995.86","volume":"37","author":"P.E. Sax","year":"2004","unstructured":"Sax PE, Kumar P: Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004, 37:1111\u20131124.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/00126334-200212153-00011","volume":"31","author":"A. Ammassari","year":"2002","unstructured":"Ammassari A, Antinori A, Cozzi-Lepri A, et al.: Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002, 31:S140\u2013S144.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"18_CR7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s11136-005-5001-2","volume":"15","author":"A. Marin","year":"2006","unstructured":"Marin A, Casado JL, Aranzabal L, et al.: Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res 2006, 15:767\u2013775.","journal-title":"Qual Life Res"},{"key":"18_CR8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/01.qai.0000214811.72916.67","volume":"41","author":"K. Mulligan","year":"2006","unstructured":"Mulligan K, Parker RA, Komarow L, et al.: Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006, 41:590\u2013597.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"18_CR9","unstructured":"Cameron DW, da Silva B, Arribas J, et al.: Significant sparing of peripheral lipoatrophy by HIV treatment with LPV\/r + ZDV\/3TC induction followed by LPV\/R monotherapy compared with EFV + ZDV\/3TC [abstract 44LB]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25\u201328, 2007."},{"key":"18_CR10","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-200212060-00010","volume":"16","author":"V. Joly","year":"2002","unstructured":"Joly V, Flandre P, Meiffredy V, et al.: Increased risk of lipoatrophy under stavudine in HIV-1 infected patients: results of a substudy from a comparative trial. AIDS 2002, 16:2447\u20132457.","journal-title":"AIDS"},{"key":"18_CR11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","volume":"14","author":"S.A. Mallal","year":"2000","unstructured":"Mallal SA, John M, Moore CB, et al.: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309\u20131316.","journal-title":"AIDS"},{"key":"18_CR12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"J.E. Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191\u2013201.","journal-title":"JAMA"},{"key":"18_CR13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","volume":"288","author":"A. Carr","year":"2002","unstructured":"Carr A, Workman C, Smith DE, et al.: Abacavir substitution for thymidine nucleoside analogues in HIV-infected patients with lipoatrophy: a randomized controlled open-label multicenter 24 week study. JAMA 2002, 288:207\u2013215.","journal-title":"JAMA"},{"key":"18_CR14","unstructured":"Moyle G, Sabin C, Cartledge J, et al.: A 48 week, randomized, open-label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART [abstract 44LB]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22\u201325, 2005."},{"key":"18_CR15","doi-asserted-by":"crossref","unstructured":"Milinkovic A, Lopez S, Vidal S, et al.: A randomized open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine [abstract 857]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22\u201325, 2005.","DOI":"10.1177\/135965350701200301"},{"key":"18_CR16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002030-200501030-00002","volume":"19","author":"G.A. McComsey","year":"2005","unstructured":"McComsey GA, Paulsen DM, Lonergan JT, et al.: Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005, 19:15\u201323.","journal-title":"AIDS"},{"key":"18_CR17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","volume":"354","author":"K. Brinkman","year":"1999","unstructured":"Brinkman K, Smeitink JA, Romijn JA, et al.: Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy lipodystrophy. Lancet 1999, 354:1112\u20131115.","journal-title":"Lancet"},{"key":"18_CR18","doi-asserted-by":"crossref","first-page":"14711","DOI":"10.1021\/bi035596s","volume":"42","author":"H. Lee","year":"2003","unstructured":"Lee H, Hanes J, Johnson KA: Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003, 42:14711\u201314719.","journal-title":"Biochemistry"},{"key":"18_CR19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/135965350300800614","volume":"8","author":"D. Nolan","year":"2003","unstructured":"Nolan D, Hammond E, James I, et al.: Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003, 8:617\u2013626.","journal-title":"Antivir Ther"},{"key":"18_CR20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","volume":"43","author":"A.L. Pozniak","year":"2006","unstructured":"Pozniak AL, Gallant JE, Dejesus E, et al.: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine\/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes \u2014 a 96-week analysis. J Acquir Immune Defic Syndr 2006, 43:535\u2013540.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"18_CR21","unstructured":"Dub\u00e9 M, Komarow L, Mulligan K, et al.: DEXA outcomes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz or both plus dual nucleosides: long-term results from A5005s, a substudy of ACTG 384 [abstract WEPE0167]. Paper presented at the XVI International AIDS Conference. Toronto, Canada; August 13\u201318, 2006."},{"key":"18_CR22","unstructured":"Haubrich RH, Riddler S, DiRienzo G, et al.: Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection [abstract 38]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25\u201328, 2007."},{"key":"18_CR23","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"A. Carr","year":"1998","unstructured":"Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51\u201358.","journal-title":"AIDS"},{"key":"18_CR24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00002030-200001070-00005","volume":"14","author":"T. Saint-Marc","year":"2000","unstructured":"Saint-Marc T, Partisani M, Poizot-Martin I, et al.: Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000, 14:37\u201349.","journal-title":"AIDS"},{"key":"18_CR25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJM199810293391806","volume":"339","author":"A. Carr","year":"1998","unstructured":"Carr A, Cooper DA: Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998, 339:1296.","journal-title":"N Engl J Med"},{"key":"18_CR26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/498505","volume":"42","author":"J.G. Jemsek","year":"2006","unstructured":"Jemsek JG, Arathoon E, Arlotti M, et al.: Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006, 42:273\u2013280.","journal-title":"Clin Infect Dis"},{"key":"18_CR27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","volume":"17","author":"P.W. Mallon","year":"2003","unstructured":"Mallon PW, Miller J, Cooper DA, Carr A: Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003, 17:971\u2013979.","journal-title":"AIDS"},{"key":"18_CR28","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","volume":"19","author":"M.P. Dube","year":"2005","unstructured":"Dube MP, Parker RA, Tebas P, et al.: Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005, 19:1807\u20131818.","journal-title":"AIDS"},{"key":"18_CR29","unstructured":"Hicks C, DeJesus E, Sloan L, et al.: Efficacy and safety of once-daily boosted fosamprenavir\/ritonavir with abacavir\/lamivudine fixed dose combination in antiretroviral naive HIV-1 infected patients: 24-week results from COL100758 [abstract P2]. Presented at the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland; November 12\u201316, 2006."},{"key":"18_CR30","unstructured":"Tashima K, Stryker R, Skeist D, et al.: Lack of clinical lipodystrophy in patients receiving efavirenz + NRTI in study 006 [abstract 1304]. Paper presented at the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 26\u201329, 1999."},{"key":"18_CR31","first-page":"114","volume":"12","author":"J. Currier","year":"2002","unstructured":"Currier J, Carpenter C, Daar E, et al.: Identifying and managing morphologic complications of HIV and HAART. AIDS Read 2002, 12:114\u2013119, 124\u2013125.","journal-title":"AIDS Read"},{"key":"18_CR32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0002-9343(89)90225-8","volume":"86","author":"C. Grunfeld","year":"1989","unstructured":"Grunfeld C, Kotler DP, Hamadeh R, et al.: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27\u201331.","journal-title":"Am J Med"},{"key":"18_CR33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","volume":"352","author":"S. Grinspoon","year":"2005","unstructured":"Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48\u201362.","journal-title":"N Engl J Med"},{"key":"18_CR34","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","volume":"289","author":"S.A. Riddler","year":"2003","unstructured":"Riddler SA, Smit E, Cole SR, et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 2003, 289:2978\u20132982.","journal-title":"JAMA"},{"key":"18_CR35","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","volume":"1","author":"F. Leth van","year":"2004","unstructured":"van Leth F, Phanuphak P, Stroes E, et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004, 1:e19.","journal-title":"PLoS Med"},{"key":"18_CR36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","volume":"354","author":"J.E. Gallant","year":"2006","unstructured":"Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251\u2013260.","journal-title":"N Engl J Med"},{"key":"18_CR37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","volume":"368","author":"J. Eron Jr","year":"2006","unstructured":"Eron J Jr, Yeni P, Gathe J Jr, et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006, 368:476\u2013482.","journal-title":"Lancet"},{"key":"18_CR38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/jac\/dki063","volume":"55","author":"M.L. Montes","year":"2005","unstructured":"Montes ML, Pulido F, Barros C, et al.: Lipid disorders in antiretroviral-naive patients treated with lopinavir\/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005, 55:800\u2013804.","journal-title":"J Antimicrob Chemother"},{"key":"18_CR39","unstructured":"Malan N, Krantz E, David N, et al.: Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 [abstract 107LB]. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5\u20138, 2006."},{"key":"18_CR40","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1086\/382531","volume":"38","author":"E. Martinez","year":"2004","unstructured":"Martinez E, Domingo P, Galindo MJ, et al.: Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004, 38:1017\u20131023.","journal-title":"Clin Infect Dis"},{"key":"18_CR41","unstructured":"Teppler H, Azrolan N, Chen J, Nguyen BY, for the Protocol 004 Study Group: Differential effect of MK-0518 and efavirenz on serum lipids and lipoproteins in antiretroviral therapy (ART)-naive patients [abstract H-0256a]. Paper presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 27\u201330, 2006."},{"key":"18_CR42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1468-1293.2005.00328.x","volume":"6","author":"S.D. Shafran","year":"2005","unstructured":"Shafran SD, Mashinter LD, Roberts SE: The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005, 6:421\u2013425.","journal-title":"HIV Med"},{"key":"18_CR43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200001070-00006","volume":"14","author":"J.Q. Purnell","year":"2000","unstructured":"Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51\u201357.","journal-title":"AIDS"},{"key":"18_CR44","unstructured":"Smith K, Weinberg W, DeJesus E, et al.: Once-daily boosted fosamprenavir (FPV\/r) or atazanavir (ATZ\/r) with tenofovir\/emtricitabine in antiretroviral naive HIV-1 infected patients: 24-week results from COL103952 (ALERT) [abstract P1]. Presented at the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland; November 12\u201316, 2006."},{"key":"18_CR45","unstructured":"Slim J, Avihingsanon A, Ruxrungtham K, et al.: Saquinavir BID vs lopinavir plus emtricitabine\/tenofovir QD in ARV-naive HIV-1 infected patients: GEMINI study [abstract PL2.5]. Paper presented at the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland; November 12\u201316, 2006."}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-007-0018-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-007-0018-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-007-0018-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T12:53:26Z","timestamp":1708174406000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-007-0018-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1007\/s11904-007-0018-5","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}